关于血液透析患者耐药肺结核治疗的最新情况
Jonny Jonny1, Paramitha Dwiputri Saraswati2, Bunga Pinandhita Ramadhani2
1Department of Internal Medicine, Gatot Soebroto Central Army Hospital, DKI Jakarta, Indonesia; Faculty of Medicine, Jakarta Veterans National Development University, DKI Jakarta, Indonesia.
The Indian journal of tuberculosis
|July 27, 2024
概括
世界卫生组织 (WHO) 的新抗药结核病 (TB) 方案,包括BPaLM和BPaL,对于血液透析 (HD) 慢性病 (CKD) 患者来说似乎是安全的. 需要进一步的研究来确认这种人群的疗效和安全性.
科学领域:
- 药理学 药理学是指药理学的学科.
- 腎臟病學 (nephrology) 是一種醫學專業.
- 传染性疾病 传染性疾病
背景情况:
- 世界卫生组织 (WHO) 在2022年更新了耐药结核病 (TB) 管理,引入了BPaLM和BPaL等较短的治疗方案.
- 慢性病 (CKD),特别是在血液透析 (HD) 患者中,可以改变结核病药物的药理动力学,可能影响治疗的疗效和安全性.
- 关于这些新型结核病治疗方案对接受血液透析的CKD患者的影响的数据有限.
研究的目的:
- 评估世卫组织推的新型耐药结核病疗法 (BPaLM,BPaL) 对血液透析 (HD) 慢性病 (CKD) 患者的安全性和潜在影响.
- 评估BPaLM/BPaL成分在功能障碍中的药理学因素和潜在毒性.
主要方法:
- 审查当前文献和世卫组织关于抗药性结核病管理的指导方针.
- 对BPaLM/BPaL成分的药物代谢和分泌途径的分析,重点是肝脏与脏清除.
- 在功能障碍的背景下,识别潜在的药物相互作用和已知的副作用 (linezolid 的血液学, bedaquiline 的 QTc 延长).
主要成果:
- BPaLM/BPaL药物的主要代谢途径主要是肝脏的,这表明在功能障碍中具有潜在的安全性.
- 虽然血液透析患者的具体研究很少,但初步发现表明没有直接归因于这些疗法的重大不良事件或损伤.
- 莱涅佐利德需要对血液学副作用进行监测,而贝达奎林需要对QTc间隔延长和心律失常保持谨慎.
结论:
- 世卫组织新的结核病治疗方案 (BPaLM,BPaL) 显示出由于肝脏代谢导致血液透析的CKD患者的安全性.
- 密切监测线索利德和贝达奎林已知的副作用在这个患者群体中至关重要.
- 对功能衰竭患者进行进一步的专门研究是必不可少的,以确定这些方案的有效性和长期安全性.
相关概念视频
01:28Pulmonary Tuberculosis V
176
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
176
01:29Pulmonary Tuberculosis I
228
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
228
01:26Pulmonary Tuberculosis IV
134
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
134
01:28Pulmonary Tuberculosis II
215
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
215
01:28Pneumonia IV: Management
315
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
315
01:31Pulmonary Tuberculosis III
316
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
The first classification is based on the development of the disease, and it includes the following categories:
316